natgillin/translations-raw huggingface dataset:
A clinically not relevant increase in the apparent clearance of nevirapine (by 9%) compared to historical data was reported. 
Poročali so o klinično nepomembnem povečanju navideznega očistka nevirapina (za 9 %) v primerjavi s prejšnjimi kontrolnimi podatki.
The clinical relevance of these data in European populations has not been established. 
Klinični pomen teh izsledkov pri evropskih populacijah še ni raziskan.
The marketing authorization holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2. of the marketing authorisation and any agreed subsequent updates of the RMP. 
Imetnik dovoljenja za promet z zdravilom bo izvedel zahtevane farmakovigilančne aktivnosti in ukrepe, podrobno opisane v sprejetem RMP, predloženem v modulu 1.8.2 dovoljenja za promet z zdravilom, in vseh nadaljnjih sprejetih posodobitvah RMP.
No clinical data available. 
Ni kliničnih podatkov.
Clarithromycin exposure was significantly decreased, 14-OH metabolite exposure increased. 
Izpostavljenost klaritromicina se je pomembno zmanjšala, izpostavljenost presnovku 14-OH pa povečala.
If liver function abnormalities recur, nevirapine should be permanently discontinued. 
Če se motnje jetrne funkcije ponovijo, moramo nevirapin trajno ukiniti.
Selected demographic and baseline disease characteristics are displayed in Table 1. 
Izbrani demografski podatki in izhodiščne značilnosti bolezni so prikazani v preglednici 1.
Pharmacokinetic data on 33 patients (age range 0.77 - 13.7 years) in the intensive sampling group demonstrated that clearance of nevirapine increased with increasing age in a manner consistent with increasing body surface area. 
Farmakokinetični podatki o 33 bolnikih (starostni razpon 0,77-13,7 leta) v intenzivni vzorčni skupini so pokazali, da se očistek nevirapina veča s starostjo, skladno s povečevanjem telesne površine.
The denominator 1,068 includes 55 patients who stopped treatment during the lead in phase and two patients randomized but never treated with randomized dose. 
Imenovalec 1.068 zajema 55 bolnikov, ki so zdravljenje prekinili med uvajalnim obdobjem in dva bolnika, ki sta bila naključno razvrščena, vendar se nikoli nista zdravila z odmerkom po naključni razvrstitvi.
Careful monitoring of paediatric patients is especially warranted, particularly in the first 18 weeks of treatment, since these patients may be less likely than adults to notice, or report, skin reactions. 
Skrbno spremljanje otrok je posebno pomembno, zlasti prvih 18 tednov zdravljenja, ker je pri njih manj verjetno kot pri odraslih, da bodo opazili kožne reakcije ali o njih obvestili zdravnika.
One case of massive accidental overdose in a newborn was reported. 
Poročali so o primeru masivnega prevelikega odmerjanja pri novorojenčku.
The required dose volumes should be measured employing the enclosed dispensing syringe and adapter, as described in steps 1-5 below. 
Potrebni volumen odmerka je treba izmeriti s priloženo merilno brizgo in adapterjem, kot je opisano v spodnjih točkah od 1 do 5.
This lead-in period should be used because it has been found to lessen the frequency of rash. 
Uvajalno obdobje je potrebno, ker se je pokazalo, da zmanjša pogostnost izpuščaja.
Nevirapine: compared to historical controls, levels appeared to be unchanged. 
Nevirapin: v primerjavi s prejšnjimi, kontrolnimi vrednostmi so bile ravni nespremenjene.
The maximum volume which can be measured with the dispensing syringe is 5 ml and therefore steps 3-5 must be repeated for dose volumes greater than 5 ml. 
Največji volumen, ki ga lahko izmerimo z merilno brizgo, je 5 ml, zato je treba za večji volumen od 5 ml postopke v točkah 3 do 5 ponoviti.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 5 February 1998 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Z ZDRAVILOM Datum prve odobritve: 5. februar 1998 Datum zadnjega podaljšanja: 20. december 2012
Boceprevir is partly metabolized by CYP3A4/5. 
Boceprevir se delno presnavlja s CYP3A4/5.
Cross-resistance between nevirapine and either HIV protease inhibitors, HIV integrase inhibitors or HIV entry inhibitors is unlikely because the enzyme targets involved are different. 
Navzkrižna odpornost med nevirapinom ter zaviralci proteaze HIV, zaviralci integraze HIV ali zaviralci vstopa HIV ni verjetna, ker so ciljni encimi različni.
You should not use Viramune on its own. 
Zdravila Viramune ne smete jemati samega.
Your doctor will carefully monitor the effect of Viramune and any of these medicines if you are taking them together. 
Vaš zdravnik bo skrbno spremljal učinek zdravila Viramune in katerega od naštetih zdravil, če ju boste jemali hkrati.
Only take Viramune tablets by mouth. 
Zdravilo Viramune tablete jemljite samo skozi usta.
These may look like whole tablets, but have not been found to affect the efficacy of nevirapine. 
Čeprav so videti kot cele tablete, ni bilo ugotovljeno, da bi to vplivalo na učinkovitost nevirapina.
Virologic failure - Never suppressed through week 48 - Rebound 
Virološki neuspeh - do vključno 48. tedna ni bilo supresije - ponovitev
Following intravenous administration to healthy adults, the volume of distribution (Vdss) of nevirapine was 1.21  0.09 l/kg, suggesting that nevirapine is widely distributed in humans. 
Po intravenskem vnosu zdravim odraslim je bil volumen porazdelitve (Vdss) nevirapina 1,21  0,09 l/kg, kar kaže, da se pri človeku obsežno porazdeli.
Because the clarithromycin active metabolite has reduced activity against Mycobacterium aviumintracellulare complex overall activity against the pathogen may be altered. 
Ker je klaritromicinov aktivni presnovek zmanjšal delovanje proti kompleksu Mycobacterium avium intracellulare, se skupno delovanje proti povzročitelju lahko spremeni.
- Latin America 
- Latinska Amerika
Nevirapine concentrations in human cerebrospinal fluid (n = 6) were 45 % ( 5 %) of the concentrations in plasma; this ratio is approximately equal to the fraction not bound to plasma protein. 
V cerebrospinalni tekočini pri človeku (n = 6) so bile nevirapinove koncentracije 45 % ( 5 %) glede na plazemske; to razmerje je približno enako frakciji, ki se ne veže na beljakovine v plazmi.
Of these 50 patients, 28 developed resistance to efavirenz and 39 developed resistance to etravirine (the most frequently emergent resistance mutation being Y181C). 
Od teh 50 bolnikov se je pri 28 razvila odpornost proti efavirenzu, pri 39 pa proti etravirinu (najpogostejša z odpornostjo povezana mutacija je bila Y181C).
For children 
Za otroke
The plasma nevirapine concentrations observed were within the range observed in adults and the remainder of the paediatric population, but were more variable between patients, particularly in the second month of age. 
Koncentracije nevirapina v plazmi so bile v območju, ki so ga zasledili pri odraslih in pri ostali populaciji otrok, vendar je bilo njihovo nihanje med posameznimi bolniki večje, zlasti v drugem mesecu starosti.
In this study, the multiple dose pharmacokinetic disposition of nevirapine and the five oxidative metabolites were not altered. 
V tej študiji se farmakokinetična dispozicija nevirapina in petih oksidativnih presnovkov ni spremenila.
43.8 and above 
43,8 in več
The total daily dose should not exceed 400 mg for any patient. 
Skupni dnevni odmerek pri nobenem bolniku ne sme preseči 400 mg.
This is especially important within the first 14 days of treatment (see more information in “How to take Viramune”). 
To je še posebej pomembno prvih 14 dni zdravljenja (glejte podrobnejše informacije v odstavku ''Kako jemati zdravilo Viramune'').
The numerator 793 is the number of patients who were treatment responders at 48 weeks (384 from immediate-release and 409 from prolonged-release treatment groups). 
Imenovalec 793 je število bolnikov z odzivom na zdravljenje po 48 tednih (384 iz skupine, ki je jemala obliko s takojšnjim sproščanjem, in 409 iz skupine, ki je jemala obliko s podaljšanim sproščanjem).
- Death - Adverse events 
- smrt - neželeni dogodki - drugo**
Decreased blood phosphorus and increased blood pressure were observed in clinical studies with coadministration of tenofovir/emtricitabine. 
Zmanjšano raven fosforja v krvi in zvišan krvni tlak so odkrili v kliničnih študijah pri sočasnem dajanju tenofovirja/emtricitabina.
Ethinyl estradiol (EE) 0.035 mg 
Etinilestradiol (EE), 0,035 mg
If patients report such an event, reassurance should be obtained on the lack of impact on therapeutic response. 
Če bolniki navedejo tak dogodek, je potrebno potrditi, da ni vplival na terapevtski odziv.
If your doctor has told you that you (or your child) have an intolerance to some sugars or you have been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before you (or your child) take or receive this medicine. 
Če vam je zdravnik povedal, da vi (ali vaš otrok) ne prenašate nekaterih sladkorjev ali če so pri vas ugotovili dedno intoleranco za fruktozo, redko genetsko bolezen, pri kateri ne morete razgraditi fruktoze, se posvetujte z zdravnikom, preden vi (ali vaš otrok) vzamete ali dobite to zdravilo.
The active substance of your medicine is called nevirapine. 
Učinkovina v vašem zdravilu se imenuje nevirapin.
By stopping reverse transcriptase from working, Viramune helps control HIV-1 infection. 
S tem, ko ustavi delovanje reverzne transkriptaze, zdravilo Viramune pomaga nadzorovati okužbo s HIV-1.
Perinatal Transmission 
Perinatalni prenos
Other information: 
Drugi podatki:
These reactions occur mainly in the first 18 weeks of treatment with Viramune. 
Pojavijo se pretežno prvih 18 tednov zdravljenja z zdravilom Viramune.
The frequency category was estimated from a statistical calculation based on the total number of patients exposed to nevirapine in randomised controlled clinical studies (n=2,718). 
Kategorijo pogostnosti so ocenili s statističnim izračunom na podlagi skupnega števila bolnikov, ki so bili izpostavljeni nevirapinu v nadzorovanih kliničnih študijah z naključno izbranimi bolniki (n = 2718).
The majority of severe rashes occurred within the first 6 weeks of treatment and some required hospitalisation, with one patient requiring surgical intervention (see section 4.4). 
Huda oblika izpuščaja se je večinoma pojavila v prvih 6 tednih zdravljenja in jo je bilo včasih treba zdraviti v bolnišnici, en bolnik pa je potreboval kirurški poseg (glejte poglavje 4.4).
Insert the syringe into the adapter. 
V adapter vstavite brizgo.
This should be taken into account in patients with diabetes mellitus. 
To morajo upoštevati bolniki s sladkorno boleznijo.
Swallow whole, do not chew, divide or crush 
Pogoltnite celo, ne žvečite, delite ali drobite.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered. 
Če pri njih zasledimo znake poslabšanja jetrne bolezni, moramo presoditi o prekinitvi ali ukinitvi tega zdravljenja.
All the randomised studies addressing this issue specifically excluded pregnant women, and pregnant women were under-represented in cohort studies as well as in meta-analyses. 
V vseh raziskavah z naključno izbiro preizkušank, v katerih so proučevali prav ta pojav, so nosečnice izključili, poleg tega je bilo število nosečnic premajhno tudi v kohortnih raziskavah in pri metaanalizah.
In addition, the observed trough nevirapine concentrations were comparable between the two methods. 
Poleg tega so bile najmanjše koncentracije nevirapina pri obeh metodah primerljive.
This is particularly suitable if: - you have problems swallowing tablets - or you are a child weighing less than 50 kg - or you are a child having a body surface area less than 1.25 square metres (your doctor will work out your surface area). 
Posebno primerna je, če: - imate težave s požiranjem tablet - ali ste otrok, lažji od 50 kg - ali ste otrok z manjšo telesno površino od 1,25 kvadratnega metra (vašo telesno površino bo določil zdravnik).
You must take it with at least two other antiretroviral medicines. 
Jemati ga morate z najmanj dvema drugima protiretrovirusnima zdraviloma.
Furthermore, in the case Viramune is used as single dose to prevent vertical transmission of HIV-1 infection, the risk of hepatotoxicity in mother and child cannot be excluded. 
Poleg tega pri uporabi zdravila Viramune v enkratnem odmerku za preprečiitev vertikalnega prenosa okužbe s HIV-1 ne moremo izključiti tveganja hepatotoksičnih učinkov pri materi in otroku.
The choice of a subsequent therapy after Viramune should be based on clinical experience and resistance testing (see section 5.1). 
Izbira zdravila, ki ga bomo uporabili po zdravilu Viramune, mora temeljiti na kliničnih izkušnjah in preskusu odpornosti (glejte poglavje 5.1.
This study demonstrated a significant reduction in transmission using single dose nevirapine (13.1 % (n = 310) in the Viramune group, versus 25.1 % (n = 308) in the ultra-short zidovudine group (p = 0.00063)). 
V njej se je ta prenos pomembno zmanjšal po uporabi enkratnega odmerka nevirapina (13,1 % (n = 310) v skupini, ki je prejemala Viramune, v primerjavi s 25,1 % (n = 308) v skupini z ultrakratkim režimom zidovudina (p = 0,00063)).
** Includes lost to follow-up, consent withdrawn, noncompliance, lack of efficacy, pregnancy, and other. 
** Zajema bolnike, za katere ni bilo podatkov o sledenju, so umaknili privolitev, niso upoštevali predpisanega zdravljenja ali zdravilo ni bilo učinkovito, nosečnice in druge bolnike.
Ribavirin does not inhibit cytochrome P450 enzymes, and there is no evidence from toxicity studies that ribavirin induces liver enzymes. 
Ribavirin ne zavira encimov citokroma P450; iz raziskav o toksičnosti pa ni dokazov, ki bi kazali, da ribavirin inducira jetrne encime.
Both, the primary (p = 0.92) and secondary endpoints showed no statistically significant differences between efavirenz and Viramune 200 mg twice daily. 
Niti primarni (p = 0,92) niti sekunddarni opazovani dogodki niso odkrili statistično značilnih razlik med efavirenzem in zdravilom Viramune po 200 mg dvakrat na dan.
There was also accumulation of nevirapine hydroxy-metabolites in plasma. 
Prišlo je tudi do kopičenja nevirapinovih hidroksiliranih presnovkov v plazmi.
Frequency is defined using the following convention: very common (1/10); common (1/100 to <1/10); uncommon (1/1,000 to <1/100); rare (1/10,000 to <1/1,000); very rare (<1/10,000). 
Razdelitev po pogostnosti: zelo pogosti (> 1/10); pogosti (> 1/100, < 1/10); občasni (> 1/1.000, < 1/100); redki (> 1/10.000, < 1/1.000); zelo redki (< 1/10.000).
This leaflet was last revised in {MM/YYYY} 
Navodilo je bilo nazadnje revidirano dne {MM/LLLL} Drugi viri informacij
Do not chew your tablets. 
Tablet ne žvečite.
* Includes 2 patients who were randomised but never received blinded medicinal products. 
* Zajema 2 bolnika, ki sta bila naključno razvrščena, toda nista nikoli prejela prikritih zdravil.
The dose must be strictly adhered to, especially the 14-days lead-in period (see section 4.2). 
Natančno je treba upoštevati navodila o odmerjanju, zlasti 14-dnevno uvajalno obdobje (glejte poglavje 4.2).
Contact your doctor if you notice changes in body fat (see section 4 “Possible side effects”). 
Če opazite spremembe telesnega maščevja, se pogovorite z zdravnikom (glejte poglavje 4 ''Možni neželeni učinki'').
3 (6.3 % versus 1.2 % for men with CD4 counts <400 cells/mm 
3 (6,3 % proti 1,2 % pri moških s številom celic CD4 < 400 celic/mm
Distribution: Nevirapine is lipophilic and is essentially nonionized at physiologic pH. 
Porazdelitev: nevirapin je lipofilen in pri fiziološki vrednosti pH pretežno neioniziran.
In the case of concomitant antiviral therapy for hepatitis B or C, please refer also to the relevant product information for these medicinal products. 
Pri sočasnem protivirusnem zdravljenju zaradi hepatitisa B ali C poglejte tudi ustrezno informacijo o zdravilih, ki jih zanj uporabljamo.
Combination therapy with nevirapine is not a curative treatment of patients infected with HIV-1; patients may continue to experience illnesses associated with advanced HIV-1 infection, including opportunistic infections. 
Kombinirano zdravljenje z nevirapinom ni kurativna oblika zdravljenja s HIV-1 okuženih bolnikov; še nadalje lahko zbolevajo za boleznimi, povezanimi z napredovano okužbo s HIV-1, tudi oportunističnimi okužbami.
There are no specific studies about the ability to drive vehicles and use machinery. 
Specifičnih raziskav o sposobnosti za vožnjo in upravljanje strojev ni na voljo.
It is recommended that HIV-infected mothers do not breast-feed their infants to avoid risking postnatal transmission of HIV and that mothers should discontinue breast-feeding if they are receiving nevirapine. 
Priporočamo, naj s HIV okužene matere ne dojijo dojenčkov, da bi se izognili tveganju poporodnega prenosa HIV, in naj prenehajo dojiti, če prejemajo nevirapin.
Nevirapine: plasma levels:  1.151.28 compared to historical controls. 
Nevirapin: raven v plazmi:  1,151,28 v primerjavi s prejšnjimi, kontrolnimi vrednostmi.
These findings are most likely related to nevirapine being a strong inducer of liver enzymes, and not due to a genotoxic mode of action. 
Njihov pojav je najverjetneje povezan s tem, da je nevirapin močan induktor jetrnih encimov, in ne z genotoksičnimi učinki.
Turn the bottle upside down and gently draw out the required amount of Viramune oral suspension. 
Plastenko obrnite in počasi odvzemite ven potrebno količino peroralne suspenzije Viramune.
This is a retrospective multicentre study comparing the 3-year antiviral efficacy of Viramune and efavirenz in combination with stavudine and lamivudine in 2NN patients from week 49 to week 144. 
To je retrospektivna multicentrična študija, v kateri primerjajo 3-letno protiretrovirusno učinkovitost zdravila Viramune in efavirenza v kombinaciji s stavudinom in lamivudinom pri bolnikih iz študije 2NN, in sicer od 49. do 144. tedna.
YOU SHOULD DISCONTINUE TAKING VIRAMUNE AND YOU MUST CONTACT your doctor IMMEDIATELY as such reactions can be potentially life-threatening or lead to death. 
TAKOJ MORATE PRENEHATI JEMATI zdravilo Viramune in se NEMUDOMA POSVETOVATI z zdravnikom, ker so lahko takšne reakcije življenjsko nevarne ali povzročijo smrt.
Cartons containing 2 blister cards (14 tablets). 
Škatle vsebujejo 2 pretisna trakova (14 tablet).
Other medicines and Viramune 
Druga zdravila in zdravilo Viramune
Primary study endpoints (percentage of patients with treatment failures) and secondary study endpoints as well as backbone therapy were similar to the original 2NN study. 
Primarni opazovani dogodki (odstotek bolnikov, pri katerih je bilo zdravljenje neuspešno) in sekundarni opazovani dogodki ter osnovno zdravljenje so bili podobni kot v originalni študiji 2NN.
In a panel of 2,923 predominantly subtype B HIV-1 clinical isolates, the mean EC50 value was 90nM. 
Pri naboru 2923 kliničnih izolatov HIV-1, pretežno podtipa B, je bila srednja vrednost EC50 90 nM.
Make sure that your child's doctor clearly tells you what dose you must give to your child. 
Poskrbite, da vam bo otrokov zdravnik jasno povedal, kolikšen odmerek mu morate dajati.
Your doctor might need to monitor whether your other medicines are still working and adjust doses. 
Zdravnik mora preveriti, ali še učinkujejo, in prilagoditi njihove odmerke.
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. 
Bolniki z obstoječo motnjo jetrne funkcije, tudi kroničnim aktivnim hepatitisom, imajo med kombiniranim protivirusnim zdravljenjem pogosteje moteno jetrno delovanje, zato jih je treba spremljati v skladu s standardno prakso.
The safety and efficacy of Viramune prolonged-release tablets in children aged less than 3 years has not been established. 
Varnost in učinkovitost zdravila Viramune tablete s podaljšanim sproščanjem pri otrocih, mlajših od 3 let, še nista bili dokazani.
For this reason, and to reduce the risk of HIV transmission, barrier contraception (e.g. condoms) is recommended. 
Iz tega razloga in zato, da bi zmanjšali nevarnost prenosa HIV, priporočamo uporabo mehanske kontracepcije (npr. kondoma).
3 with detectable HIV-1 RNA in plasma (50 or more copies/ml), these conditions should be taken in consideration on therapeutic decision (see section 4.4). 
HIV-1 RNA v plazmi (50 ali več kopij/ml), je treba ta stanja pri odločitvi o zdravljenju upoštevati (glejte poglavje 4.4).
- Europe 
- Evropa
Granulocytopenia was more frequently observed in children. 
Granulocitopenija je bila pogostejša pri otrocih.
Cartons containing 6 or 12 blister cards (60 or 120 tablets). 
Škatle vsebujejo 6 ali 12 pretisnih omotov (60 ali 120 tablet).
All of these effects subsided following discontinuation of nevirapine. 
Vsi našteti učinki so po ukinitvi nevirapina minili.
Therefore, caution should be used in concomitant administration. 
Zato je pri sočasnem dajanju potrebna previdnost.
Nevirapine stops reverse transcriptase from working. 
Nevirapin ustavi delovanje reverzne transkriptaze.
PHARMACEUTICAL FORM AND CONTENTS 240 ml oral suspension 
FARMACEVTSKA OBLIKA IN VSEBINA 240 ml peroralne suspenzije
In clinical studies, Viramune has been associated with an increase in HDL- cholesterol and an overall improvement in the total to HDL-cholesterol ratio. 
V kliničnih študijah so zdravilo Viramune povezovali s povečanjem HDL holesterola in splošnim izboljšanjem razmerja med skupnim holesterolom in HDL holesterolom.
Six cases of Stevens-Johnson Syndrome were reported in the study; all but one occurred within the first 30 days of nevirapine treatment. 
V študiji so poročali o šestih primerih Stevens-Johnsonovega sindroma; vsi razen enega so se pojavili v prvih 30 dneh zdravljenja z nevirapinom.
Because of the risk of increased exposure to Viramune, caution should be exercised if the medicinal products are given concomitantly and patients should be monitored closely. 
Zaradi nevarnosti povečane izpostavljenosti zdravilu Viramune moramo biti pri sočasnem dajanju teh zdravil previdni in bolnike skrbno spremljati.
The most common clinical toxicity of nevirapine is rash. 
Najpogostnejši klinični toksični učinek nevirapina je izpuščaj.
Numerous studies have been performed examining the use of Viramune in regards to perinatal transmission, most notably HIVNET 012. 
O uporabi zdravila Viramune v povezavi s perinatalnim prenosom so izvedli številne raziskave, med katerimi je zlasti pomembna HIVNET 012.
No changes to lamivudine apparent clearance and volume of distribution, suggesting no induction effect of nevirapine on lamivudine clearance. 
Ni sprememb navideznega očistka lamivudina in volumna porazdelitve, kar kaže, da nevirapin nima indukcijskega učinka na očistek lamivudina.
PHARMACEUTICAL FORM Oral suspension 
FARMACEVTSKA OBLIKA peroralna suspenzija
Your doctor might then decide to restart you on a lower dose. 
Pozneje vam lahko zdravljenje ponovno uvede in vam predpiše manjši odmerek.
The simultaneous use of nevirapine (400 mg) plus efavirenz (800 mg) was associated with the highest frequency of clinical adverse events and with the highest rate of treatment failure (53.1 %). 
Pri sočasni uporabi nevirapina (400 mg) in efavirenza (800 mg) je bila pogostnost kliničnih neželenih učinkov največja, največji pa je bil tudi odstotek neuspešnega zdravljenja (53,1 %).
If you forget to take Viramune 
Če ste pozabili vzeti zdravilo Viramune
It is important that you continue taking Viramune correctly, as described above, unless your doctor instructs you to stop. 
Pomembno je, da nadaljujete s pravilnim jemanjem zdravila Viramune, kot je opisano v tem navodilu, razen kadar vam zdravnik naroči, da prenehate.
Other nevirapine formulations, such as immediate-release tablets or oral suspension should be used (see section 4.2). 
Uporabiti je treba druge oblike nevirapina, kot so tablete s takojšnjim sproščanjem ali peroralna suspenzija (glejte poglavje 4.2).
Patients with hepatic impairment should be monitored carefully for evidence of medicinal product induced toxicity. 
Bolnike z jetrno okvaro je treba skrbno spremljati, da bi odkrili znake toksičnosti zdravila.